Qiming U.S. Ventures Management, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 7, 2024), Qiming U.S. Ventures Management, LLC reported 6 stock positions worth $51.4 million. Its top holding was Tourmaline Bio (TRML) at 37.1% of the portfolio, followed by Jasper Therapeutics (JSPR, 34.0%) and Korro Bio (KRRO, 23.9%). Its holdings were unchanged from Q2 2024.
- Most Recent 13F
- Q3 2025
- Location
- BELLEVUE, WA
- CIK
- 0001909617
- Portfolio Value
- $51.4M (Q3 2024)
- SEC Filing
- 0001104659-24-115326 ↗ filed Nov 7, 2024
Holdings Value
Holdings 6 stocks · $51.4M
| TRML Tourmaline Bio Inc. | 37.12% | 741,691 | $19.1M | No change |
| JSPR Jasper Therapeutics Inc. | 34.02% | 928,964 | $17.5M | No change |
| KRRO Korro Bio Inc. | 23.95% | 368,085 | $12.3M | No change |
| HLVX Hillevax Inc. | 1.92% | 558,923 | $984K | No change |
| VTYX Ventyx Biosciences Inc. | 1.75% | 412,225 | $899K | No change |
| KEZAR LIFE SCIENCES INC | 1.24% | 828,711 | $638K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| None this quarter. | |||
Portfolio Buys Q2 2024 → Q3 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 4 | $55.6M | TRML, KRRO, JSPR, KZR |
| Q2 2025 | 6 | $23.6M | TRML, JSPR, KRRO, VTYX, HLVX |
| Q1 2025 | 6 | $23.1M | TRML, KRRO, JSPR, HLVX, VTYX |
| Q4 2024 | 6 | $51.1M | JSPR, TRML, KRRO, VTYX, HLVX |
| Q3 2024 | 6 | $51.4M | TRML, JSPR, KRRO, HLVX, VTYX |
| Q2 2024 | 6 | $52.6M | JSPR, KRRO, TRML, HLVX, VTYX |
| Q1 2024 | 6 | $89.7M | KRRO, JSPR, TRML, HLVX, VTYX |